Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...

Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C ...

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculate | This ...

After unlocking commercial supply and enlisting a manufacturing partner earlier this year, Ferring Pharmaceuticals has ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...